MHT vs. veins: is there any reason to fear?

Grzegorz Stachowiak

doi:10.5114/pm.2013.33422

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2013
vol. 12

Send email

Copy url:

abstract:

Review paper

MHT vs. veins: is there any reason to fear?

Grzegorz Stachowiak

Przegląd Menopauzalny 2013; 1: 52–56

DOI: https://doi.org/10.5114/pm.2013.33422

Online publish date: 2013/03/05

View full text Get citation

PlumX metrics:

Venous thromboembolism (VTE) is both a contraindication and a complication of menopausal hormone therapies (MHT). This article presents a review of up-to-date literature on VTE epidemiology and its risk factors, paying attention mostly to the impact of MHT on VTE risk, starting from the 1970s reports to the North American Menopause Society position statement of 2012. The risk of VTE is minimized by the proper patients’ qualification (e.g. elimination of risk factors, 50-59-aged patients), choice of transdermal MHT, hormone dose reduction and proper progestogen choice.

keywords:

MHT vs. veins: is there any reason to fear?

Grzegorz Stachowiak

menopause, hormone therapy, transdermal therapy, progestogens